Printer Friendly

Poliovirus Excretion in Children with Primary Immunodeficiency Disorders, India.

Oral polio vaccine (OPV) has been a key factor in global polio eradication and has proven highly effective because of its ease of administration and ability to transmit to secondary contacts (1-4). Primary immunodeficiencies (PIDs) are a heterogeneous group of inherited disorders resulting from developmental defects or dysfunction of the immune system components (5). Patients with PID can potentially be infected by immunizations if they receive live vaccines (6). OPV immunization has been associated with poliovirus infection in patients with primary antibody deficiencies and combined immunodeficiencies, which can lead to paralysis (7,8). In addition, some vaccinated patients with PID may shed vaccine-derived polioviruses (VDPVs) because of a prolonged period of intestinal replication. VDPVs show increased nucleotide divergence in the viral protein 1 (VP1) coding region in all variants of OPV serotypes (PV1, PV2, and PV3); this divergence is associated with increased neuropathogenicity (9). More than 100 immunodeficiency-related VDPV (iVDPV) infections have been reported in PID patients worldwide to date (10,11). As potential reservoirs for neurovirulent VDPV strains, patients with PID represent a global risk to nonimmunized contacts and to the Global Polio Eradication Initiative (10,12).

Several studies have investigated iVDPVs in patients with different types of immunodeficiencies, such as combined immunodeficiency, antibody deficiency, and other immunodeficiencies (8,10,13,14). Recognizing the risk that iVDPV poses to global poliovirus eradication, the World Health Organization (WHO) maintains a registry of known iVDPV cases and promotes global surveillance of iVDPVs (15). However, it is difficult to estimate the number of iVDPV excreters worldwide in the absence of systematic screening of immunodeficient patients for enterovirus excretion, especially in the developing world (15).

To establish screening facilities for children with PID in India, we collaborated with the National Institute of Immunohaematology (NIIH, the referral laboratory for PID in India) and Bai Jerbai Wadia Children's Hospital (a tertiary care unit) in Mumbai, India, which has established facilities for diagnosis of PIDs. The study aimed to identify the proportion of children with PID who have enterovirus infection and also to identify long-term polio/nonpolio enterovirus excreters among them.

Materials and Methods

Study Design

The study is being conducted in collaboration with the clinicians of the PID surveillance group at NIIH and Wadia Children's Hospital. This article describes the data regarding children with PID who were enrolled in the study during September 2014-April 2017. Blood samples were collected at Wadia Children's Hospital from patients ([less than or equal to] 18 years of age) suspected of having immunodeficiencies, as part of routine surveillance; diagnosis was confirmed by standard procedure at NIIH.

We obtained ethical clearance from the Ethics Committee of NIIH, Wadia Children's Hospital, and Enterovirus Research Centre (ERC), Mumbai, and obtained informed consent from the patients' parents. The investigations were guided by the clinical presentation, immunological abnormalities, and molecular diagnosis wherever feasible, according to the phenotypic classification of the International Union of Immunological Societies (affiliated with WHO) (16). Initial investigations involved a complete blood count with a differential count on the leukocytes and mean platelet volume on a Sysmex XS-800i 5-part automated hematological analyzer (Sysmex Co., Kobe, Japan); serum immunoglobulin estimation (IgG, IgA, IgM, IgE) by nephelometry (BNProspec, Siemens); nitroblue tetrazolium blood test by microscopy; and lymphocyte subset analysis by flow cytometry using BD Multitest 6-color TBNK reagent (BD Biosciences, San Jose, CA, USA) to determine percentages and absolute number of B cells (CD19); T cells (CD3); T-helper cells (Th, CD3, and CD4); T-cytotoxic cells (Tc, CD3, and CD8); and natural killer (NK) cells (CD3 negative and CD16 or CD56). We performed flow cytometry-based assays on FACS ARIA-I using the stain-lyse-wash method and analyzed them with FACS Diva software (BD Biosciences). We made specific PID diagnoses on the basis of clinical features and laboratory investigations (16,17).

We collected fecal samples from the children with PID who routinely visit the PID outpatient department of Wadia Children's Hospital for checkup and intravenous immunoglobulin (IVIG) treatment. We followed up with these patients regularly for monthly fecal samples (1 sample in each month for 2 consecutive months); both Wadia Children's Hospital and ERC staff reminded patients to return with their samples. ERC performed fecal sample processing (as described later), culture, isolation, and characterization of virus isolates. We followed up by taking monthly samples from the patients whose samples were found positive for enteroviruses until 2 consecutive samples became negative for enteroviruses. We followed up again with those patients for enterovirus detection after a 6-month interval.

Enterovirus Isolation

We performed enterovirus isolation from fecal extracts as described in the WHO laboratory manual (18). We used human rhabdomyosarcoma (RD) and transgenic mouse cell line expressing polio receptor (L20B) for enterovirus culture. We treated fecal extracts (10%, wt/vol) prepared in phosphate-buffered saline (Sigma cat. no. D8662; Sigma-Aldrich, St. Louis, MO, USA) with 10% (vol/vol) chloroform before inoculation in cell cultures. We infected cells in duplicate with 200 [mciro]L of stool extract, incubated at 36[degrees]C, and observed microscopically for cytopathogenic effect (CPE) daily for 5 days. We freeze-thawed cell cultures showing CPE and collected culture medium for virus identification. We scored samples as negative if 2 consecutive passages in the same cell line did not produce CPE.

Enterovirus Typing

We extracted viral RNA from culture medium of CPE-positive freeze-thawed cells using a QIAamp Viral RNA Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. For nonpolio enteroviruses, we used primer pairs 222/224 and 88/89 for partial VP1 sequencing for identification of enterovirus type (19,20). For poliovirus isolate VP1 region amplification ([approximately equal to] 900 nt), we performed reverse transcription PCR in a single tube using reverse primer Q8 and forward primer Y7, as described previously (21). We performed the sequencing using a BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. We resolved the sequences on an ABI 3130xl Genetic Analyzer (Applied Biosystems) and edited them using Sequencher version 4.10.1 software (Gene Codes, Ann Arbor, MI, USA). For nonpolio enteroviruses, we subjected the sequences to BLAST search (https://www.ncbi.nlm.nih. gov/BLAST) and defined the virus type using the criteria of [greater than or equal to] 75% nucleotide and [greater than or equal to] 85% amino acid similarity in the VP1 region (22). For poliovirus isolates, we compared sequences with the Sabin reference strain in the VP1 region.


A total of 1,393 patients with suspected PID were screened at the PID Outpatient Department of Wadia Children's Hospital during a period of 2 years and 7 months; of these, the NIIH PID screening group confirmed that 151 patients had PID. We were able to follow up with 42 patients with humoral, combined, and other PIDs for fecal sample collection to test for enterovirus excretion. There were 33 male and 9 female participants. We found a striking predominance of male participants in all types of PID except IgG subclass deficiency. The age of the study participants ranged from 4 months to 18 years of age (Table 1). The PID types showed a mixture of antibody deficiencies, combined T and B cell deficiencies, phagocytic defects, and other immunodeficiencies (Table 1).

Of 42 children with PID, 40 (95%) had received OPV 1-96 months before fecal specimen collection; the parents of the remaining 2 (5%) children were not able to recall whether their children had received OPV. All patients with antibody-mediated immunodeficiency were under replacement IVIG prophylaxis. We collected fecal samples before the monthly IVIG therapy was administered. Of the 42 patients enrolled for the study, 5 (11.9%) underwent bone marrow transplant and 10 (23.8%) died during the study period.

We received 105 fecal samples from 42 patients with confirmed PID; we tested these for polio and other entero viruses. Among the fecal samples from these 42 patients, specimens of 8 patients (19%) tested positive for enteroviruses. Of these, we found 1 patient with severe combined immunodeficiency (SCID) who had excreted poliovirus for 2 years and then abruptly stopped excreting it. Fecal specimens of a 4-month-old patient with SCID and 1 patient with familial hemophagocytic lymphohistiocytosis (FLH) tested positive for poliovirus (Sabin type 1) (Table 2). A total of 4 patients with SCID were enrolled in this study; SCID was diagnosed in 2 of them at 2 months of age, and fecal specimens collected for detection of enterovirus excretion were found negative. Both the patients died before the second sample collection. Samples from 3 patients with antibody deficiencies and 2 patients with other immunodeficiencies tested positive for nonpolio enterovirus (NPEV), but subsequent samples tested negative (Table 3). None of the samples from patients with common variable immune deficiency (CVID) tested positive for enterovirus excretion.

Poliovirus Excretors

A 6-year-old boy with a case of leaky SCID had been excreting poliovirus for 2 years. Genetic sequencing of virus isolates identified type 3 VDPV with up to 41 (4%) nt changes at 4 years of age, which subsequently showed up to 93 (10%) nt divergence in VP1 region (from the parental Sabin strain) at 6 years of age. After a prolonged excretion for 2 years, the child abruptly stopped excreting; subsequent collections were found negative for poliovirus. The child had received routine immunizations, as well as Pulse Polio doses on National Immunization Days, until he was 14 months of age; he was also immunized with IPV at 3.5 years of age. The first and second samples from a 4-month-old child with SCID tested positive for Sabin1 poliovirus (separate samples collected each month until patient becomes negative for enterovirus excretion); as of this writing, the third sample is due for collection. The fecal specimen of another patient with FLH tested positive for poliovirus in the second sample, but 2 subsequent samples were negative (Table 2). This child was being treated for FLH but had peripheral demyelinating neuropathy unrelated to this disease, and died 5 days after the fourth specimen collection.

One patient with X-linked agammaglobulinemia (XLA) was enrolled in our study; this patient had a previous record of VDPV2 excretion detected by acute flaccid paralysis (AFP) surveillance by the National Polio Surveillance Program (NPSP, WHO) being conducted at our center. The child had a paralytic attack 3 months after receiving the last dose of OPV, 2 years before enrollment in our study. Case history showed detection of VDPV2 through AFP surveillance, with 7 nt changes from the parent virus. The child was routinely receiving replacement IVIG therapy because of suspected PID; subsequent specimens tested for poliovirus excretion were found negative. No virus shedding was detected in the monthly specimens collected after this child was enrolled in our study.

Nonpoliovirus Excreters

Five (12%) patients tested positive for nonpolio enteroviruses; 1 patient with IgG subclass deficiency excreted enterovirus 75 (EV-75) and 1 patient with XLA excreted EV-76 in only 1 specimen each. These 2 patients were receiving IVIG replacement therapy and being followed up for enterovirus excretion. A patient with the rare immunodeficiency disorder dedicator of cytokinesis 8 deficiency (DOCK8 deficiency, or hyper IgE syndrome) excreted echovirus 13 in the first fecal sample, and another patient with the rare immunodeficiency disorder B cell expansion with NF-kB and T cell anergy (BENTA) disease excreted echovirus 5 in the first fecal sample. The patient with DOCK8 deficiency was lost to follow-up; repeated monthly samples from the patient with BENTA disease tested negative for enterovirus. The first specimen from a patient having chronic granulomatous disease, a phagocytic disorder, tested positive for echovirus 14, but the patient died before the next specimen collection (Table 3).


Children with PID are at risk for prolonged infection with enteroviruses and may excrete iVDPV after receiving OPV or after being exposed to contacts excreting poliovirus. Such patients are at risk for developing paralytic poliomyelitis and must be identified, as they may pose a risk of reintroduction of the virus into the population after global eradication of poliovirus.

The first objective of this study was to identify chronic or long-term poliovirus/nonpolio enterovirus excreters among children with various PIDs being treated at a tertiary care unit in Mumbai. Although there was no chronic (>5 years) poliovirus excreter among the participants, we identified 1 patient with SCID as a long-term (>6 months) VDPV3 excreter who was excreting VDPV for 2 years. One of the notable highlights of our study was that 6 (75%) of 8 children with PID who were excreting enterovirus had combined or other immunodeficiencies, rather than only antibody-mediated immunodeficiency. Madkaikar et al. reported the distribution pattern of PID in the same tertiary care unit in Mumbai, which varied considerably from those reported by United States, Europe, Africa, and other Asian countries, as follows: diseases of immune dysregulation (29%), phagocytic defects (29%), predominant antibody deficiency (13%), combined T and B cell deficiency (19%), and other well-defined diseases (10%) (17). Our study showed a similar pattern of distribution in PID participants: diseases of immune dysregulation (31%), predominant antibody deficiency (34%), phagocytic defects (17%), and combined T and B cell deficiency (14%). Except for 1 patient (a VDPV2 excreter), none of the participants had paralytic disease at the time of enrollment in the study or developed paralysis during the study period.

The VDPV3 isolates excreted by the patient with SCID showed 4% nucleotide change at 4 years of age, indicating that the source of virus was most probably the OPV given at birth. The patient has been receiving IVIG at regular intervals since he received the diagnosis of SCID. In an outbreak of poliovirus infection in Minnesota, USA, in 2005, a patient with PID continued to shed iVDPVs while receiving immunoglobulin therapy for several months and finally stopped shedding virus after a second bone marrow transplant (23). According to the WHO Update on VDPVs (24,25), 6 patients with SCID, 5 of them with no paralytic manifestations, were excreting VDPV2 for a long time (>4 months to several years), and 1 continued virus excretion even after a bone marrow transplant. Unlike a Sri Lanka study (14) that reported that children with SCID may not pose a threat to the community because of their short life span, our study, along with studies in Israel, Iran, Libya, and Turkey (24,25), showed that some patients with SCID can excrete the virus for a prolonged period even after bone marrow transplant, with a high rate of nucleotide changes from the parent Sabin strain. The life expectancy of these children varies depending on the type of SCID/mutation, so it is necessary to analyze the immunological workup of these patients for visualizing whether the child can survive or excrete viruses. Another striking feature common to these SCID poliovirus excreters is that most of them excrete VDPV without exhibiting any paralytic symptoms. Of the 4 participants with SCID in our study, 2 of them received their diagnoses at 2 months of age; their fecal specimens were found negative for enteroviruses, but the infants died before the next sample collection at the age of 4 months. One reason for the survival of 1 child with SCID could be that his condition was diagnosed as leaky SCID (26), whereas the 2 infants who died exhibited classical SCID. Further studies on the patient with leaky SCID are in progress to enumerate the changes in immunological parameters that might have contributed to stopping virus excretion. The information about this child was provided to NPSP for screening of contacts and other precautionary measures.

FLH accounted for the largest number of patients in our study, which enrolled 11 patients with FLH. The reason could be that the FLH treatment protocol requires frequent hospitalization and follow-up, so the patients with FLH were therefore accessible for fecal sample collection. One of the children with FLH excreted Sabin1 poliovirus only once, and subsequent specimens tested negative.

The incidence of agammaglobulinemia has been estimated to be [approximately equal to]1/100,000 live births in the United States and Europe, but no estimates have been made for developing countries (27). We enrolled 7 patients with XLA (17%), ranging in age from 20 months to 18 years; all of them had received routine OPV and are currently undergoing IVIG replacement therapy. One patient with XLA had a history of early demyelination with Guillain-Barre syndrome and onset of paralysis; VDPV2 was detected in this patient at 10 months of age through the WHO AFP surveillance program. Aside from patients with SCID, patients with B cell-mediated PIDs such as XLA and CVID have been reported to excrete VDPVs (14,25,28). There are controversies regarding replacement IVIG therapy preventing enterovirus infections in B cell deficiency disorders (29,30). In our study, the role of IVIG in stopping VDPV shedding cannot be ruled out for the patient with SCID who excreted VDPV3 and the patient with XLA who excreted VDPV2.

Eight (19%) of 42 participants were excreting enteroviruses with no associated disease, which can be considered normal for most enterovirus infections. The excretion of enteroviruses in our study was not restricted to antibody-mediated immunodeficiency; rather, it included patients with different spectrums of PID, although there was only 1 long-term excreter. Three patients had CVID, but none of them has excreted enteroviruses so far, as reported in other studies (14,31). The reason could be that all 3 participants received their diagnoses after the age of 7 years and would thus have had their diagnoses missed by either AFP or PID surveillance, as all of them are asymptomatic (31,32).

Our data have limitations in that they represent the PID participants in a tertiary care unit in Mumbai, India, restricting the study population to only Mumbai and parts of Maharashtra state. Patient follow-up, sharing of fecal samples, and collection of specimens at regular intervals were challenging because of lack of awareness and financial burden. Although 151 patients with diagnosed PID were recorded during our study period, only 42 could be followed up. Our study does not allow a precise quantification of the risk for prolonged excretion of poliovirus among patients with PID because there was only 1 patient who excreted for >6 months. Because we used the RD and L20B cell lines for isolation of enteroviruses, we could have missed some enteroviruses that are not cultivable in these cell lines. Furthermore, owing to the lack of affordable treatment and expensive clinical management of infants and children with persistent and chronic infections, many young children probably died from PID before diagnosis. Because our study included only children [less than or equal to] 18 years of age, persons with CVID who often do not develop signs or symptoms of immune deficiency until they are young adults would have been missed (33). Some patients with B cell immunodeficiency could not be followed, so this study may not be an accurate reflection of all patients with B cell immunodeficiency disorders.

Our study demonstrated that the proportion of children who have PID and enterovirus infection in the study area is not high, which may indicate that the risk of chronic excretion of poliovirus among patients with PID in India is low. However, owing to sample size limitations, we recommend future studies expanding the scope and intensity of surveillance activities at additional referral hospitals in other areas of the country. A large-scale multicenter study is needed for the determination of the pattern of excretion of poliovirus in children in India who have received diagnoses of PID.


We thank Swapnil Varose and C.B. Sawant for their help in fecal sample collection and data entry and the staff of the Isolation Lab of the Enterovirus Research Centre for their technical assistance. We acknowledge the National Polio Surveillance Program, World Health Organization, for the Polio Lab Facility.

This study was supported by intramural funds from the Indian Council of Medical Research, New Delhi, India.

Dr. Mohanty is a research scientist at Enterovirus Research Centre, Indian Council of Medical Research, Mumbai, India. Her primary research interest is innate immune responses to polio and nonpolio enteroviruses.


(1.) World Health Organization. Progress towards global interruption of wild poliovirus transmission, January 2011-March 2012. Wkly Epidemiol Rec. 2012;87:195-200.

(2.) Sutter RW, Kew OM, Cochi S, Aylward B. Poliovirus vaccine--live. In: Plotkin, SA, Orenstein, W, Offit, PA, editors. Vaccines, 6th ed. Philadelphia: Elsevier; 2012. p. 598-645.

(3.) Benyesh-Melnick M, Melnick JL, Rawls WE, Wimberly I, Oro JB, Ben-Porath E, et al. Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. Am J Epidemiol. 1967;86:112-36.

(4.) Chen RT, Hausinger S, Dajani AS, Hanfling M, Baughman AL, Pallansch MA. et al. Seroprevalence of antibody against poliovirus in inner-city preschool children. Implications for vaccination policy in the United States. JAMA. 1996;275:1639-45. 10.1001/jama.1996.03530450029028

(5.) Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol. 2015;35:696-726. s10875-015-0201-1

(6.) Eibl MM, Wolf HM. Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities. Immunotherapy. 2015;7:127-392.

(7.) Guo J, Bolivar-Wagers S, Srinivas N, Holubar M, Maldonado Y. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. Vaccine. 2015;33:1235-42. j.vaccine.2015.01.018

(8.) Shaghaghi M, Shahmahmoodi S, Abolhassani H, Soleyman-Jahi S, Parvaneh L, Mahmoudi S, et al. Vaccine-derived polioviruses and children with primary immunodeficiency, Iran, 1995-2014. Emerg Infect Dis. 2016;22:1712-9. eid2210.151071

(9.) Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses--worldwide, April 2011-June 2012. MMWR Morb Mortal Wkly Rep. 2012;61:741-6.

(10.) Diop OM, Burns CC, Sutter RW, Wassilak SG, Kew OM; Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses--worldwide, January 2014-March 2015. MMWR Morb Mortal Wkly Rep. 2015;64:640-6.

(11.) Jorba J, Diop OM, Iber J, Sutter RW, Wassilak SG, Burns CC; Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses--worldwide, January 2015-May 2016. MMWR Morb Mortal Wkly Rep. 2016;65:763-9.

(12.) Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587-635. 58.030603.123625

(13.) Driss N, Ben-Mustapha I, Mellouli F, Ben Yahia A, Touzi H, Bejaoui M, et al. High susceptibility for enterovirus infection and virus excretion features in Tunisian patients with primary immunodeficiencies. Clin Vaccine Immunol. 2012;19:1684-9.

(14.) de Silva R, Gunasena S, Ratnayake D, Wickremesinghe GD, Kumarasiri CD, Pushpakumara BA, et al. Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in Sri Lanka. Vaccine. 2012;30:7561-5.

(15.) Li L, Ivanova O, Driss N, Tiongco-Recto M, da Silva R, Shahmahmoodi S, et al. Poliovirus excretion among persons with primary immune deficiency disorders: summary of a seven-country study series. J Infect Dis. 2014;210(Suppl 1):S368-72.

(16.) Bousfiha A, Jeddane L, Al-Herz W, Ailal F, Casanova JL, Chatila T, et al. The 2015 IUIS Phenotypic Classification for Primary Immunodeficiencies. J Clin Immunol. 2015;35:727-38.

(17.) Madkaikar M, Mishra A, Desai M, Gupta M, Mhatre S, Ghosh K. Comprehensive report of primary immunodeficiency disorders from a tertiary care center in India. J Clin Immunol. 2013;33:507-12.

(18.) World Health Organization. Manual for the Virological Investigation of Polio. Geneva: The Organization; 2004.

(19.) Oberste MS, Maher K, Kilpatrick DR, Pallansch MA. Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to picornavirus classification. J Virol. 1999;73:1941-8.

(20.) Nix WA, Oberste MS, Pallansch MA. Sensitive, seminested PCR amplification of VP1 sequences for direct identification of all enterovirus serotypes from original clinical specimens. J Clin Microbiol. 2006;44:2698-704. JCM.00542-06

(21.) Kilpatrick DR, Iber JC, Chen Q, Ching K, Yang SJ, De L, et al. Poliovirus serotype-specific VP1 sequencing primers. J Virol Methods. 2011;174:128-30. j.jviromet.2011.03.020

(22.) Oberste MS, Maher K, Kilpatrick DR, Flemister MR, Brown BA, Pallansch MA. Typing of human enteroviruses by partial sequencing of VP1. J Clin Microbiol. 1999;37:1288-93.

(23.) Alexander JP, Ehresmann K, Seward J, Wax G, Harriman K, Fuller S, et al.; Vaccine-Derived Poliovirus Investigations Group. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. J Infect Dis. 2009;199:391-7.

(24.) Jorba J, Diop OM, Iber J, Sutter RW, Wassilak SG, Burns CC; Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses--worldwide, January 2015-May 2016. MMWR Morb Mortal Wkly Rep. 2016;65:763-9.

(25.) Halsey NA, Pinto J, Espinosa-Rosales F, Faure-Fontenla MA, da Silva E, Khan AJ, et al.; Polio Project Team. Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull World Health Organ. 2004;82:3-8.

(26.) Shearer WT, Dunn E, Notarangelo LD, Dvorak CC, Puck JM, Logan BR, et al. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol. 2014;133:1092-8.

(27.) Shahmahmoodi S, Mamishi S, Aghamohammadi A, Aghazadeh N, Tabatabaie H, Gooya MM, et al. Vaccine-associated paralytic poliomyelitis in immunodeficient children, Iran, 1995-2008. Emerg Infect Dis. 2010;16:1133-6. eid1607.091606

(28.) Foiadelli T, Savasta S, Battistone A, Kota M, Passera C, Fiore S, et al. Nucleotide variation in Sabin type 3 poliovirus from an Albanian infant with agammaglobulinemia and vaccine associated poliomyelitis. BMC Infect Dis. 2016;16:277.

(29.) Hammon WM, Coriell LL, Wehrle PF, Stokes J Jr. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. IV. Final report of results based on clinical diagnoses. J Am Med Assoc. 1953;151:1272-85.

(30.) Halliday E, Winkelstein J, Webster AD. Enteroviral infections in primary immunodeficiency (PID): a survey of morbidity and mortality. J Infect. 2003;46:1-8. jinf.2002.1066

(31.) Global Polio Eradication Initiative. Polio pipeline No. 8--summer 2011 [cited 2017 Apr 8]. polio-pipeline-no-8-summer-2011/

(32.) Centers for Disease Control and Prevention (CDC). Prolonged poliovirus excretion in an immunodeficient person with vaccineassociated paralytic poliomyelitis. MMWR Morb Mortal Wkly Rep. 1997;46:641-3.

(33.) Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92:34-48. clim.1999.4725

Address for correspondence: Madhu C. Mohanty, Scientist-E, Enterovirus Research Center, Indian Council of Medical Research, Haffkine Institute Campus, Acharya Donde Marg, Parel, Mumbai-400012, India; email:

Author affiliations: Enterovirus Research Centre, Mumbai, Maharashtra, India (M.C. Mohanty, U.P. Nalavade, D.K. Sharma, J.M. Deshpande); National Institute of Immunohaematology, Mumbai (M.R. Madkaikar, M. Gupta, A. Dalvi, S. Shabrish, M. Kulkarni, J. Aluri); Bai Jerbai Wadia Children's Hospital, Mumbai (M. Desai, P. Taur)

Table 1. Baseline characteristics of confirmed PID cases in children
recruited from Wadia Children's Hospital, Mumbai, India, September
2014-April 2017 *

Serial                PID types                  No.     M/F     Age
                                                cases   ratio   range,
1         Hemophagocytic lymphohistiocytosis     11     10/1     4-96
2            X-linked agammaglobulinemia          7      7/0    27-216
3           Chronic granulomatous disease         4      3/1     7-60
4          Severe combined immunodeficiency       4      4/0     4-48
5          Common variable immunodeficiency       3      2/1    84-120
6              Chediak-Higashi syndrome           3      1/2    26-86
7               Hypogammaglobulinemia             2      1/1    96-108
8              IgG subclass deficiency            2      0/2    84-114
9                 Hyper-IgM syndrome              2      2/0    17-59
10          Autoimmune lymphoproliferative        1      0/1      15

11        B cell expansion with NF-[kappa]B       1      1/0      18
                  and T cell anergy
12                Hyper-IgE syndrome              1      1/0      42
13         Interleukin 12 receptor [beta]1        1      1/0     156
Total                   defect                   42     33/9    4-216

* PID, primary immunodeficiency

Table 2. Demographic and clinical data for patients with PID whose
fecal samples tested positive for polioviruses, Wadia Children's
Hospital, Mumbai, India, September 2014-April 2017 *

Serial   Age, mo/               Months last      IVIG
no.        sex      PID type   OPV ([dagger])   therapy   BMT

1          48/M       SCID           37           Yes     ND

2          48/M       FLH            NA           No      ND
3          4/M        SCID           4            Yes     ND

no.                      Results by collection day

1         D1, VDPV3; D91, VDPV3; D175, VDPV3; D207, VDPV3; D263,
            VDPV3; D334, VDPV3; D369, VDPV3; D454, VDPV3; D488,
            VDPV3; D524, VDPV3; D550, VDPV3; D634, VDPV3; D700,
             VDPV3; D774, neg; D799, Neg; D840, neg; D930, neg
2                D1, neg; D49, P1SL; D128, neg; D241, neg
3                           D1, P1SL; D29, P1SL

* BMT, bone marrow transplant; D, day of collection following first
collection; FLH, familial lymphohistiocytosis; IVIG, intravenous
immunoglobulin; NA, not available; ND, not done; neg, negative; OPV,
oral polio vaccine; P1SL, polio1 Sabin-like; P3SL, polio 3
Sabin-like; PID, primary immunodeficiency disease; SCID, severe combined
immunodeficiency; VDPV3, type 3 vaccine-derived poliovirus.

([dagger]) Time from last OPV to first fecal sample collection.

Table 3. Demographic and clinical data for patients with PID whose
fecal samples tested positive for nonpolio enteroviruses, Wadia
Children's Hospital, Mumbai, India, September 2014-April 2017 *

Serial   Age, mo/                  Months from    IVIG
no.        sex        PID type      last OPV     therapy   BMT

1         114/F     IgG subclass       60          Yes     ND
2          42/M      Hyper-IgE         24          No      ND
3          18/M        BENTA           NA          No      ND
4          30/M         CGD            NA          No      ND
5          54/M         XLA             1          Yes     ND

no.                 Results by collection day

1        D1, neg; D62, EV75; D214,neg; D250, neg; D419,
                    neg; D476, neg; D685, neg
2                  D1, E13; lost to follow-up

3                 D1, E5; D185, neg; D273, neg

4                      D1, E14; D10, died
5           D1, EV76; D107, neg; D136, neg; D260, neg

* BENTA, B cell expansion with NF-[kappa]B and T cell anergy; BMT,
bone marrow transplant; CGD, chronic granulomatous disease; D, day of
collection following first collection; E5, echovirus 5; E13, echovirus
13; E14, echovirus 14; EV75, enterovirus 75; EV76, enterovirus 76;
IVIG, intravenous immunoglobulin; NA, not available; ND, not done;
neg, negative; OPV, oral polio vaccine; PID, primary immunodeficiency
disease; XLA, X-linked agammaglobulinemia.

([dagger]) Time from last OPV to first fecal sample collection.
COPYRIGHT 2017 U.S. National Center for Infectious Diseases
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:RESEARCH
Author:Mohanty, Madhu Chhanda; Madkaikar, Manisha Rajan; Desai, Mukesh; Taur, Prasad; Nalavade, Uma Prajwal
Publication:Emerging Infectious Diseases
Article Type:Report
Geographic Code:9INDI
Date:Oct 1, 2017
Previous Article:Antimicrobial Drug Prescription and Neisseria gonorrhoeae Susceptibility, United States, 2005-2013.
Next Article:November 2016: Bacterial Pathogens.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters